ArticleScientific reports2025
Boric acid-functionalized bentonite nanostructures attenuated paraquat-induced pulmonary injuries in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study evaluated the antioxidant, anti-inflammatory, and anti-fibrotic effects of boric acid-functionalized bentonite nanostructures (BABTs) in a rat model of paraquat (PQ)-induced pulmonary toxicity, a well-established model for herbicide-related lung fibrosis. BABTs (20-60 nm) were synthesized via a microwave-assisted technique, characterized by dynamic light scattering, scanning electron microscopy, Fourier-transform infrared, and ultraviolet-visible spectroscopy, confirming PQ-BABT complex formation. Forty-eight male Wistar rats were randomized into eight groups (n = 6/group): negative control (saline), positive control (single 100 mg/kg PQ oral dose), and experimental groups receiving BABTs or boric acid (BA) at 10, 50, or 100 mg/kg/day orally, 30 min post-PQ. After 14 days, lung malondialdehyde (MDA) levels and histopathological changes (H&E, Masson's Trichrome) were assessed. BABTs at 50 mg/kg significantly decreased lung malondialdehyde (MDA) levels (P < 0.05) and significantly attenuated tissue injury (P < 0.05), suggesting an attenuation of oxidative stress, inflammation, and fibrosis, while boric acid (BA) demonstrated no significant effect. BABTs mitigate PQ-induced lung injury through antioxidant, anti-inflammatory, and anti-fibrotic mechanisms, enhanced by reducing PQ bioavailability. These findings position BABTs as a promising therapeutic candidate for PQ-induced pulmonary fibrosis, warranting further clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.